We are losing the war against stimulants because we refuse to pay for the one thing that actually stops people from using them.
For decades, the public health establishment has searched for a magic bullet to treat methamphetamine and cocaine addiction. We have poured billions of dollars into pharmaceutical research, behavioral talk therapies, and punitive prison sentences. Yet overdose deaths involving psychostimulants continue to climb. Amid this crisis, a highly effective treatment exists, backed by over thirty years of rigorous clinical data. It is called contingency management. It is a behavioral therapy that quite literally pays people to stay sober. You might also find this connected coverage insightful: Inside the Congo Ebola Crisis Nobody is Talking About.
But we do not use it.
We do not use it because the concept of giving target gift cards, cash, or vouchers to active drug users offends our collective moral sensibilities. We would rather watch people die of preventable overdoses than hand them a twenty-dollar bill for a clean urine sample. This political and social squeamishness is costing thousands of lives every year. As reported in recent coverage by National Institutes of Health, the effects are worth noting.
The Simple Neuroscience of the Cash Reward
To understand why paying people to stay sober works, you have to understand what stimulants do to the human brain.
Drugs like methamphetamine and cocaine do not just make people feel good. They hijack the brain's dopamine reward pathway, the ancient evolutionary engine that motivates us to eat, drink water, and reproduce. A normal, healthy brain experiences a spike in dopamine when we accomplish a task or share a meal with family. Stimulants flood this system with up to ten times the normal level of dopamine. The brain adapts quickly. It shuts down its natural dopamine production, rendering the user incapable of feeling joy from everyday activities.
Talk therapy cannot easily compete with that level of chemical rewiring.
Traditional rehab programs rely on the promise of long-term rewards. They offer the hope of a restored career, repaired family relationships, and improved physical health months or years down the road. But an addict in the throes of withdrawal is not operating on a timeline of months. They are operating on a timeline of hours. Their hijacked brain demands immediate relief.
Contingency management solves this problem by introducing an immediate, tangible counter-stimulus.
Under a typical program, a patient comes to a clinic two or three times a week to provide a urine sample. If the sample is negative for stimulants, they receive a reward on the spot. It might be a voucher, a gift card, or a chance to draw a prize from a bowl. The first clean test might yield a reward worth five dollars. Each consecutive clean test increases the value of the reward. If the patient tests positive, the reward level resets to zero, and they have to start building their streak again.
It is simple. It is immediate. And it is incredibly powerful because it speaks the exact same neurological language as the addiction itself.
The reward acts as a surrogate dopamine trigger. It gives the brain a small, clean victory to look forward to every forty-eight hours. Over time, these small rewards keep patients in treatment long enough for their natural brain chemistry to heal. Once the brain recovers its baseline dopamine function, the patient can begin to appreciate the long-term benefits of sobriety, like getting a job or rebuilding relationships.
Why Stimulants Demand a Different Approach
The crisis of stimulant abuse is fundamentally different from the opioid epidemic, yet we treat them with the same playbook.
For opioid use disorder, we have highly effective medications. Methadone and buprenorphine stabilize the brain's opioid receptors, cutting cravings and preventing withdrawal. These medications allow people to lead stable, productive lives. They are the gold standard of care.
We have no such medications for methamphetamine or cocaine.
Despite decades of clinical trials, the Food and Drug Administration has approved exactly zero pharmacological treatments for stimulant addiction. There is no suboxone for meth. There is no patch, no pill, and no injection that can stop a cocaine craving. When a patient walks into an addiction clinic seeking help for a severe methamphetamine habit, clinicians are essentially empty-handed. They can offer counseling, support groups, and empathy. But the drop-out rates for these traditional programs are notoriously high.
Most stimulant users leave treatment within the first month.
Contingency management is the only intervention that consistently keeps stimulant users engaged in treatment. Dozens of randomized controlled trials funded by the National Institutes of Health have reached the same conclusion. When you pay patients for clean drug screens, they stay in treatment longer, they use fewer drugs, and they experience longer periods of continuous abstinence.
The data is not subtle. It is overwhelming. Yet, if you walk into almost any addiction treatment center in the United States today, you will not find contingency management on the menu.
The Cost of Our Moral Outrage
The primary barrier to implementing this treatment is not scientific. It is ideological.
When politicians and the general public hear about contingency management, the immediate reaction is almost always anger. Critics argue that we are rewarding bad behavior. They ask why tax dollars should go toward buying groceries or household goods for people who broke the law, while hard-working, sober citizens receive no such bonuses. They call it bribery.
This moral outrage is an expensive luxury.
Consider the alternative. When a person with a severe stimulant addiction does not get effective treatment, the public pays for it anyway. We pay for it through emergency room visits, ambulance rides, cardiovascular surgeries, psychiatric hospitalizations, and foster care placements. We pay for it through the policing, court costs, and incarceration fees required to process them through the criminal justice system.
A single day in a state prison costs taxpayers more than an entire three-month course of contingency management.
A typical, highly effective contingency management program costs roughly eight hundred dollars per patient in total incentives spread over twelve weeks. In contrast, a single visit to an emergency department for a methamphetamine-induced psychotic episode can easily run into thousands of dollars. From a purely financial standpoint, refusing to fund contingency management is a fiscal disaster.
We are choosing to spend tens of thousands of dollars on punishment and emergency care rather than hundreds of dollars on a cure, simply because the cure feels too much like a gift.
Our collective obsession with punitive justice has blinded us to pragmatic medicine. We treat addiction as a moral failing that must be punished, rather than a chronic brain disease that must be managed. If a diabetic patient needs financial assistance to afford insulin, we might debate the logistics, but we do not generally accuse them of having a character flaw. Yet, when we suggest using minor financial incentives to treat a disease that destroys the brain's decision-making apparatus, we recoil in disgust.
The Bureaucratic Trap Keeping Patients Sick
Even when clinicians want to use contingency management, they run into a wall of federal and state regulations.
The biggest hurdle is a set of federal laws designed to prevent healthcare fraud. The anti-kickback statute was written to stop corrupt doctors from giving patients financial kickbacks to inflate Medicare and Medicaid billing. Because contingency management involves giving patients cash-equivalent rewards, federal regulators have historically viewed these programs with extreme suspicion.
For years, the federal Office of Inspector General capped the value of incentives that clinics could give to patients at a measly seventy-five dollars per year.
An incentive of seventy-five dollars spread over twelve months is completely useless. It is too small to compete with the immediate pull of a drug craving. To be clinically effective, the rewards must be frequent and substantial enough to matter to the patient. Research shows that the sweet spot is around seventy-five to one hundred dollars per week in the initial phases of treatment, tapering off as sobriety is established.
By keeping the cap so low, federal regulators effectively outlawed the only evidence-based treatment we have for stimulant addiction.
Some progress has been made in recent years, but it is painfully slow. A few states have successfully petitioned the federal government for Medicaid waivers to run pilot programs. California, for instance, launched a recovery incentive program under its CalAIM initiative, allowing Medicaid reimbursement for contingency management. Montana and Washington have also taken tentative steps to implement these programs on a broader scale.
But these efforts are still treated as boutique experiments rather than standard medical practice. They are bogged down by administrative tracking requirements, strict caps on lifetime incentive limits, and endless red tape. Clinicians must jump through hoops to prove that a twenty-dollar grocery voucher was not used to purchase alcohol or tobacco, adding administrative costs that dwarf the cost of the incentives themselves.
While we debate the logistics of gift cards, the body count grows.
Decoupling Medicine from Morality
If we want to make a dent in the stimulant crisis, we have to stop treating addiction treatment as a test of moral fitness.
We must accept that the human brain is a biological machine governed by chemistry, not a spiritual vessel governed solely by willpower. When that machine is broken by highly addictive synthetic drugs, we must use whatever tool works to fix it. If that tool happens to be a weekly voucher for Walmart or a local supermarket, then we should distribute those vouchers with the same urgency that we distribute Naloxone.
We do not have the luxury of waiting for a perfect pharmaceutical cure that may never arrive. We do not have the luxury of holding out for every patient to find spiritual enlightenment in a traditional twelve-step meeting. We have a crisis of empty clinic waiting rooms, devastated families, and overflowing morgues.
The science is settled. The economics are clear. The only remaining obstacle is our own discomfort.
